Elizabeth Ioannacci, APN Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 5926 Crawfordsville Rd Unit B, Speedway, IN 46224 Phone: 317-653-2730 Fax: 317-623-1440 |
News Archive
HRA Pharma (http://www.hra-pharma.com), a privately-held, European pharmaceutical company that designs products, devices and supporting services in reproductive health and endocrinology, announced today that ellaOne(R) (ulipristal acetate, 30mg), its new generation emergency contraceptive, has been launched in France, Germany and the United Kingdom via local HRA teams. HRA Pharma will progressively launch ellaOne in all European countries over the coming months.
A novel treatment for blood clots in the legs appears to be safe and effective, according to a pilot study published in the February issue of Radiology.
Maybe turning to sleep gadgets - wristbands, sound therapy and sleep-monitoring smartphone apps - is a good idea. A new University of Oregon-led study of middle-aged or older people who get six to nine hours of sleep a night think better than those sleeping fewer or more hours.
Mutations in genes are the basis of evolution, so we owe our existence to them. Most mutations are harmful, however, because they cause cells to build defective proteins. So cells have evolved quality control mechanisms that recognize and counteract genetic mistakes.
Ranbaxy Laboratories Limited announced today that the Company has received approval from the U.S. Food and Drug Administration to manufacture and market Fenofibrate Capsules USP, 43 mg and 130 mg. The Office of Generic Drugs, U.S. Food and Drug Administration, has determined the Ranbaxy formulations to be bioequivalent and have the same therapeutic effect as that of the reference listed drug Antara Capsules, 43 and 130 mg, respectively, of Lupin Atlantis.
› Verified 8 days ago